The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
those two histologies uh patients with those two histologic types of cancer could respond and ultimately response rates in those two diseases turned out to be about 15 to 20% of patients with about a third of those patients having complete durable uh durable regressions
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
and so we grew those cells one out of peripheral blood but we also grew cells invading into tumor called tumor infiltrating lymphocytes or till cells we grew them in vitro and in animal and then very quickly in human experiments grew those lymphocytes to large numbers in vitro and administered them to patients with metastatic melanoma and now instead of the 15% response rate that we got from giving uh interlukin 2 Alone by giving lymphocytes that we grew in interlukin 2 these till cells we got response rates 30 35% in melanoma patients